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For almost half a century, inotropes have been administered to preterm infants with 
the ultimate goal of increasing their blood pressure. A number of trials, the majority 
of which focused on dopamine administration, have demonstrated increased blood 
pressure following inotrope administration in preterm infants and have led to continued 
use of inotropes in our neonatal units. We have also seen an increase in the number 
of potential agents available to the clinician. However, we now know that hypotension 
is a much broader concept than blood pressure alone, and our aim should instead 
be focused on improving end organ perfusion, specifically cerebral perfusion. Only a 
limited number of studies have incorporated the organ-relevant hemodynamic changes 
and long-term outcomes when assessing inotropic effects in neonates, the majority of 
which are observational studies or have a small sample size. In addition, important con-
siderations, including the developing/maturing adrenergic receptors, polymorphisms of 
these receptors, and other differences in the pharmacokinetics and pharmacodynamics 
of preterm infants, are only recently being recognized. Certainly, there remains huge 
variation in practice. The lack of well-conducted randomized controlled trials addressing 
these relevant outcomes, along with the difficulty executing such RCTs, leaves us with 
more questions than answers. This review provides an overview of the various inotropic 
agents currently being used in the care of preterm infants, with a particular focus on their 
organ/cerebral hemodynamic effects both during and after transition.
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inTRODUCTiOn
For almost half a century, inotropes have been administered to preterm infants with the ultimate goal 
of increasing mean arterial blood pressure (MBP). A number of trials, the majority of which focused 
on dopamine, have demonstrated increased MBP following inotrope administration in preterm 
infants. We have recently seen an increase in the number of potential inotropic agents available to 
the clinician with tailored therapeutic regimes advocated (1).
Continued reliance on MBP to initiate therapy and guide response remains the norm (2). 
However, hypotension is a much broader concept. A limited number of studies have incorporated 
organ-relevant hemodynamic changes and long-term outcomes when assessing inotropic effects, the 
majority of which are observational studies or have been limited by small sample size. In addition, 
important considerations including the maturing adrenergic receptors, polymorphisms, and other 
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differences in the pharmacokinetics and pharmacodynamics of 
preterm infants are only recently being considered (3).
The lack of well-conducted RCTs addressing relevant outcomes, 
along with the difficulty in executing such trials (4), leaves us with 
more questions than answers. This review provides an overview 
of the various inotropic agents currently being used in the care of 
preterm infants, with a particular focus on hemodynamic effects, 
challenges in safe administration and why it is difficult to conduct 
RCTs in this area.
DOPAMine AnD DOBUTAMine
Few large RCTs have been performed investigating the effect of 
dopamine and/or dobutamine in preterm infants with hypoten-
sion or signs of low organ perfusion, but numerous observational 
studies and reviews have been published (5–7).
Dopamine is the most studied inotrope in preterm infants. 
It increases MBP (8–10) through its inotropic and vasopressor 
qualities. Dopamine is the direct precursor of noradrenaline 
(NA). It positively stimulates the α- and β-adrenoceptors, induc-
ing both vascular smooth muscle and heart muscle contraction. 
The effects on cardiac output (CO) and end organ flow remain 
largely unanswered but are probably dose specific, with higher 
doses potentially inducing a significant increase in SVR which 
may attenuate its positive inotropic effect, highlighting the poten-
tial inotrope/afterload imbalance associated with some inotropes 
(8, 11). Dopamine administration not only results in increased 
serum dopamine levels but also in NA and epinephrine levels 
(12, 13). In these infants, endogenous catecholamine levels may 
already be high after birth (14).
Dobutamine is a synthetic catecholamine, stimulating β1-
receptors, increasing CO, and reducing smooth muscle contrac-
tion resulting in peripheral vasodilation and a lower MBP increase 
when compared with dopamine (9, 10). It has been suggested as 
an alternative to dopamine; however, the different mechanisms 
of action might make it more suitable for certain disease states in 
the preterm infant.
Various parameters have been studied for the assessment of end 
organ blood flow. CO, mainly left ventricular output (LVO), has 
been described in a number of trials. A meta-analysis (15) com-
paring dopamine to dobutamine in hypotensive preterm infants 
concluded that dopamine led to a greater increase in MBP, whereas 
dobutamine had a greater effect on LVO. Clinically relevant out-
comes such as IVH, PVL, or mortality were no different. An RCT 
including 41 preterm infants with low SVC flow (<41 ml/kg/min) 
were randomized to either dopamine or dobutamine after receiv-
ing a volume bolus. The results showed that although dobutamine 
resulted in a lower MBP, it had a significantly larger increase in 
SVC flow than dopamine (mean, +9.9 versus −3.2  ml/kg/min, 
P = 0.02). 40% failed to increase/maintain SVC flow in response 
to either agent and no differences in mortality or morbidity were 
found (16). More recently Bravo et  al. randomized 28 preterm 
infants with low SVC to either dobutamine or placebo (17). The 
majority of infants achieved and maintained an SVC flow ≥ 41 ml/
kg/min after intervention and infants treated with dobutamine 
(n = 16) showed a higher heart rate (HR) and improved base excess 
compared with those treated with placebo (n = 12).
Two studies have assessed the effect on surrogate markers 
of cerebral blood flow. Using xenon techniques, Lundstrøm 
et  al. found dopamine administered at 5 μg/kg/min resulted in 
increased BP and LVO, but no change in cerebral blood flow, in 
preterm infants with an MBP between 29 and 40 mmHg (18). This 
would suggest that dopamine results in a degree of vasoconstric-
tion, either directly from its effect on cerebral vasculature or from 
a compensatory autoregulatory effect from the increase in systemic 
BP. This lack of increased cerebral perfusion was also suggested 
from fetal sheep studies where the dopamine-induced increased BP 
resulted in a cerebral autoregulatory α-adrenergic vasoconstrictive 
response, maintaining cerebral blood flow (19). However, in a sub-
sequent RCT comparing dopamine versus epinephrine in preterm 
infants with low BP, Pellicer and colleagues measured the effects 
on cerebral oxygenation as a surrogate for cerebral perfusion (20). 
They found no difference in the increase in cerebral oxygenation, 
suggesting an increase in cerebral perfusion from both drugs.
While there are few RCTs addressing end organ perfusion 
there are numerous observational studies reporting effects 
including right ventricular output (RVO), LVO, pulmonary 
pressures, and cerebral blood flow. One report on the effect of 
dopamine on right ventricular performance included hypoten-
sive preterm neonates in whom right ventricular end systolic 
volume decreased approximately 30%, whereas right ventricular 
end diastolic volume did not change. Ejection fraction therefore 
increased and RVO increased from 90 to 112 ml/kg/min (21). 
Specifically in preterm infants with septic shock, in whom 
either dopamine or dobutamine was commenced, RVO and 
HR increased, but LVO and organ flow did not. After analyzing 
subgroups, both drugs did not seem to significantly increase 
both LVO and RVO. The increase in HR was mainly seen after 
dopamine infusion (22). The effect on pulmonary artery pres-
sure was described by Liet et al. in 19 preterm ventilated infants 
(4 ± 3 days of life), with a patent ductus arteriosus (PDA), show-
ing an overall increase in arterial pulmonary pressure following 
dopamine administration (23).
Seri et  al. found an increased BP and urinary output in 
preterm infants (<2  days) following dopamine administration, 
but no change in mesenteric and cerebral perfusion indices (24). 
Contradictive results have been reported on the effect of dopa-
mine on cerebrovascular autoregulation in infants. Wong et al. 
found an increased potential for cerebral flow and metabolism 
coupling, suggesting an improved blood supply in response to 
demand (25). Contrary to these findings, Eriksen et  al. found 
dopamine had an adverse effect on cerebrovascular autoregula-
tion in preterm infants (26). A meta-analysis of predominantly 
observational studies investigating the effect of dopamine showed 
an overall increased cerebral blood flow (27). They concluded 
from 8 small studies (n = 5–36) containing a total of 153 preterm 
infants, that the increase in CBF was greater in hypotensive than 
in normotensive preterm infants. This effect was not repeated 
in newborn piglets, in which dopamine neither increased CO 
nor cerebral blood flow (28). Using NIRS as a method to assess 
cerebral perfusion in 71 preterm infants without a PDA, a modest 
increase in cerebral oxygen saturation was seen, both after volume 
and after dopamine administration (29). Volume administration 
did not alter cerebral oxygen extraction in a small population of 
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preterm infants with clinical signs of poor perfusion (30). The 
previously mentioned meta-analysis showed no statistically 
significant differences in adverse neurological outcome between 
dopamine and dobutamine (three studies; N = 118; r = −0.13; 
95% CI = −0.31 to 0.059) (27).
ADRenALine AnD nA
Adrenaline is typically used as a second or third line agent in 
the management of hypotension (2). One RCT compared 
adrenaline to dopamine in preterm infants <32 weeks gestation 
with low BP. MBP showed a significant increase from baseline 
throughout the first 96 h with no differences between groups but 
adrenaline caused a greater increase in HR and glucose levels 
more likely to need insulin. They also had higher plasma lactate 
and lower bicarbonate and base excess values (31). This increase 
in serum lactate may limit the use of sequential serum lactate 
measurements to monitor the changes in the perfusion status. As 
mentioned previously, both low/moderate-dose dopamine and 
low-dose adrenaline increased cerebral perfusion, as indicated 
by the increase in both CBV and HbD measured by NIRS (20).
Noradrenaline is a naturally occurring sympathomimetic 
amine which exerts its cardiogenic effects through activation 
of α- and β-adrenoceptors. NA poorly stimulates the vascular 
β-adrenoceptors and has a greater effect on peripheral vascular 
resistance, making it potentially useful in profound hypotension 
and septic shock (32). Rios et al. examined trends in treatment 
of neonatal hypotension and found that NA was used in 0.6% of 
admissions (33). To date, there are no RCTs assessing the efficacy 
of NA in neonatal cardiovascular compromise, and the available 
evidence is predominantly from observational trials. Concerns 
around NA’s potentially potent vasoconstrictor effect has resulted 
in limited use in preterm infants as it could lead to decreased CO 
and as a consequence poor tissue perfusion (34, 35). Liem retro-
spectively examined the use of NA in babies born 29–39 weeks 
gestation. NA succeeded in increasing BP in all babies with 
hypotension but half required another agent to achieve normo-
tension (36). Rowcliff et al. retrospectively examined the use of 
NA in infants born less than 32 weeks gestation and found it was 
effective in increasing MBP. Although tachycardia could be a side 
effect, no other adverse effects were identified (37). Barrington 
et al. report the effects of NA in 30 preterm infants with septic 
shock, highlighting an increase in MBP and urine output follow-
ing administration (38).
In adults and older children with septic shock, NA is the 
inotrope of choice due to the presence of low SVR (39). NA 
administration was also associated with increased urine output 
and decreased lactate suggesting an improvement in cardiac 
function and tissue perfusion (40). Derleth used NA in 29 infants 
born between 22 and 38 weeks gestation with septic shock and 
found less incidence of PVL in those treated with NA suggest-
ing that despite its vasoconstrictor properties, NA succeeds in 
maintaining a steady cerebral and myocardial blood flow (41).
Animal studies have shown that NA increases SVR and 
pulmonary blood flow and therefore improves outcome in pul-
monary hypertension (42). Tourneux et al. examined this effect in 
infants born >35 weeks gestation with PPHN and demonstrated 
improved lung and cardiac function (43). A recent adult study 
found NA was associated with more enterocyte damage, which 
might be an important factor to consider in preterm infants (44).
vASOPReSSin
Arginine vasopressin (AVP) is a naturally occurring neuropeptide 
secreted by the posterior pituitary gland. AVP has little or no 
inotropic or chronotropic effect, instead it exerts its actions on the 
vasculature V1 receptors resulting in arterial vasoconstriction and 
the V2 receptors of the renal tubule leading to reabsorption of renal 
free water. The majority of our evidence in preterm infants is from 
observational studies in refractory hypotension where administra-
tion of vasopressin results in an improvement in MBP, urinary 
output and HR without increasing lactate (45–51). Rios and Kaiser 
compared vasopressin to dopamine for treatment of hypotension 
in extremely low birth weight infants (52). Both were shown to be 
effective in increasing systemic BP, but vasopressin was associated 
with a reduction in PaCO2, surfactant use, and tachycardia.
Adult studies have demonstrated a reduced level of plasma 
vasopressin in patients with septic shock (53). This depletion of 
vasopressin is also evident in pediatric patients, in which small 
doses of vasopressin resulted in improved systemic BP and urine 
output (54, 55). Meyer et al. compared response to vasopressin in 
three infants with septic shock to three infants with non-septic 
shock. While vasopressin resulted in increased BP and urine 
output in both groups, the results were transient in the non-septic 
shock infants. Septic shock infants had a reduced HR and lactate 
level whereas the opposite occurred in the non-septic shock 
group (56). Many studies note a decrease in requirement of other 
inotropic agents following initiation of vasopressin to maintain/
increase BP (47, 55). Vasopressin has also been shown to increase 
the sensitivity of vasculature to NA (57).
A potential side effect is poor end organ perfusion (58, 59). 
However, the majority of studies involving vasopressin document 
its use in refractory hypotension or septic shock in which end 
organ involvement is often present before initiation (60). There 
are no data regarding its effect on CO and cerebral blood flow in 
preterm infants.
Vasopressin has potential benefit in the treatment of PPHN. In 
animal studies, vasopressin results in the reduction of pulmonary 
arterial pressures and the pulmonary:systemic ratio (61). One 
small observational study in 10 infants with PPHN found that 
administration of vasopressin resulted in improved oxygenation, 
BP, urine output, and a reduced iNO requirement (62). Similar 
findings were noted in patients with congenital diaphragmatic 
hernias where vasopressin also resulted in improved left ventricu-
lar function and oxygenation index (63). The role of vasopressin 
in the management of circulatory instability in preterm infants 
remains to be determined.
MiLRinOne
Milrinone is a selective phosphodiesterase III inhibitor in cardiac 
myocytes and vascular smooth muscle. It has potent vasodilator 
and inotropic effects leading to a reduction in afterload by decreas-
ing pulmonary vascular resistance (64–66). Milrinone is excreted 
TABLe 1 | Randomized control trials and measurement of end organ perfusion.
RCT Agents no. 
enrolled
Gestation 
(weeks)/birth 
weight (g)
LvO RvO SvC 
flow
Cerebral 
perfusion/
blood flow
Gi 
Perfusion
Urine 
output
Lactate
Roze et al. (8) Dop versus Dob 20 <32 x
Greenough et al. (9) Dop versus Dob 40 <34
Klarr et al. (10) Dop versus Dob 63 ≤34 x
Osborn et al. (16) Dop versus Dob 42 <30 x x
Chatterjee et al. (92) Dop versus Dob 20 <32 x x
Hentschel et al. (93) Dop versus Dob 20 25–36 x
Ruelas-Orozco et al. (94) Dop versus Dob 66 1,000–1,500
Gill et al. (95) Dop versus volume 39 <1,501
Lundstrøm et al. (18) Dop versus volume 36 <33 x x
Bravo et al. (17) Dob versus placebo 127 <31 x x x
Cuevas et al. (96) Dop versus placebo 49 700–2,000 x x
Pellicer et al. (20)
Valverde et al. (31)
Dop versus Adr 60 <32 x x x
Phillipos et al. (97) Dop versus Adr 20 >1,750 x x
Rios and Kaiser (52) Dop versus vasopressin 20 ≤30 x x
Paradisis et al. (75) Milrinone versus placebo 90 <30 x x x
x, outcome has been reported; LVO, left ventricular output; RVO, right ventricular output; SVC, superior vena cava; GI, gastrointestinal; Dop, dopamine; Dob, dobutamine;  
Adr, adrenaline.
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by the kidneys with little or no metabolism (67), therefore, plasma 
concentration largely depends on renal function. Paradisis et al. 
demonstrated a longer half-life in preterms (68) and Giaccone 
et al. found newborns with PPHN had reduced clearance (69).
Animal studies have demonstrated an improvement in right 
ventricular function and pulmonary vascular resistance (70, 71). 
These findings are consistent with studies involving children 
post-cardiac surgery (64, 72). However, the cAMP levels are 
decreased in the newborn myocardium, thus newborns may be 
less sensitive to the effect of milrinone (73, 74).
Paradisis conducted one of the few RCTs comparing an agent 
to placebo in preterm infants (75). Ninety infants born <30 weeks 
gestation were randomized to either milrinone or placebo. They 
showed no significant difference in SVC flow between the two 
groups. Jain et al. utilized targeted neonatal echocardiography to 
measure LVO in preterm infants post PDA ligation. Babies with 
LVO < 200 ml/kg/min received IV milrinone, and this group was 
compared with a historic cohort of babies with the same echocar-
diographic findings post ligation. Those that received milrinone 
had significantly lower ventilation failure rates, oxygenation 
failure, and need for inotropic support or steroids, suggesting 
improved cardiovascular stability (76). Previous studies have 
advised caution with administration of milrinone as it transiently 
reduced MBP (77, 78) although little is mentioned on end organ 
perfusion. Paradisis found significantly lower MBP and a higher 
HR at 7 and 10 h compared with placebo but no significant dif-
ference in hypotension (defined as an MBP < 24 mmHg). It is 
important to highlight that this study enrolled all babies at risk of 
low SVC flow as opposed to babies with established hypotension 
or low-flow states.
Due to its effect on PVR, it may have a useful role in the treat-
ment of PPHN. Samiee-Zafarghandy et al. looked at milrinone use 
in Neonatal Intensive Care Units (NICU) in North America (79). 
Milrinone was used in 0.4% of infants, and the main indication 
for use (42%) was PPHN. There are a number of observational 
studies regarding its use in PPHN (77, 78, 80, 81). Additional use of 
milrinone resulted in a reduction in oxygenation index and mean 
airway pressure. In babies with iNO resistant PPHN, milrinone 
resulted in improved LVO, RVO, and ultimately a reduction in 
iNO requirement (82). RCTs in older children with septic shock 
demonstrated an improved CO post-milrinone administration 
(83); however, such studies are lacking in preterm infants.
PRACTiCAL ADMiniSTRATiOn 
CHALLenGeS
In addition to the pharmacodynamics, pharmacokinetics, and 
pharmacogenetics of inotrope use in preterm infants, delivery 
kinetics play an important role and must be considered when 
observing effects. This is especially the case in low-flow rate con-
tinuous IV drugs, such as vasoactive drugs for preterm infants, 
where flow rates of 0.1–1 ml/h are not uncommon (84). These 
very low-flow rates combined with relatively significant dead 
space volumes lead to longer time to onset and steady state of 
intended doses, and therefore unintended highly variable and 
unpredictable doses may occur after dosing changes (85). The 
longer duration for the actual intended dose to be delivered, for 
drugs with narrow therapeutic indices, can result in significant, 
unrecognized, and potentially hazardous situations (84).
Several non-patient-specific factors have been studied that 
might influence this flow rate variability during low-flow rates, 
which are summarized to the set flow rate, hydrostatic pressure 
changes and compliance of the complete IV administration system 
“from pump to patient,” and type of substances administered (86).
wHAT iS neXT?
Despite 50 years of use, we still have little evidence regarding end 
organ perfusion and outcome of the various drugs used for both 
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hypotension and low-flow states in preterm infants. It remains 
unclear whether cerebral perfusion is increased, unaltered, or 
reduced with any inotrope use. The effects are most likely medi-
ated by alterations in systemic BP, pulmonary vascular resistance, 
a direct effect on cerebral vasculature, altered cerebrovascular 
autoregulation, or a combination of all of the above. Utilization 
of more objective assessment methods may allow us to gain better 
insight into these effects (87).
Conducting trials of inotropes in preterm infants has proven 
challenging on a number of fronts. The majority of the RCTs to 
date have been conducted in the 1990s with few of these reporting 
clinically important end points (Table 1). Over the last 10 years, 
improvements in perinatal care such as antenatal steroid exposure 
and changes in ventilation management have seen a reduction 
in the incidence of low BP in preterm infants. Achieving timely 
informed consent has proved problematic, and as such enrollment 
has been difficult resulting in very few recent trials to inform the 
neonatal community. Two small pilot trials have been conducted 
comparing dopamine to vasopressin (20 infants) and dobutamine 
to placebo (28 infants). A recent randomized trial highlighted 
practical challenges, where 10 newborns from a potential popula-
tion of 127 babies were enrolled across 16 sites (88, 89). A recent 
trial of cardiovascular compromises again highlighted challenges 
in enrollment in trials of cardiovascular support (90). It is clear that 
it is proving difficult to perform studies that require enrollment 
within a short-time window when newborn infants are unstable 
and often require prompt intervention (91). Until such issues are 
addressed, we will continue to utilize agents that may be of no 
benefit, or potentially have adverse consequences. Institutional 
review boards, regulatory authorities, funding agencies, and 
parental organizations need to be aware of these challenges, and 
an international approach to the problem is required. The recently 
established International Neonatal Consortium may have a very 
important role to play in highlighting these challenges and facilitat-
ing the conduct of high quality trials of investigational medicinal 
products, in particular inotropes, in the next number of years.
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